Stay updated with breaking news from Zionexa us corp. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
NCCN Guidelines® for clinicians and patients now recommend the use of FES PET for ER+ positive disease under certain circumstances during the systemic staging workup of patients with recurrent. | May 24, 2023 ....
(1) GE Healthcare to scale Zionexa s FDA-approved PET imaging agent, Cerianna (fluoroestradiol F-18), used as an adjunct to biopsy for the detection of estrogen receptor (ER) positive lesions to help inform treatment selection for patients with recurrent or metastatic breast cancer Aims to make Cerianna available to 75% of metastatic breast cancer patients in the U.S. by 2023 Acquisition demonstrates GE Healthcare s commitment to its precision health vision and builds additional pipeline of oncology and neurology tracers to help physicians personalize treatment GE Healthcare today announced the acquisition of Zionexa, a leading innovator of in-vivo oncology and neurology biomarkers that help enable more personalized healthcare. The company aims to develop and bring to market Zionexa s pipeline biomarkers, as well as the recently FDA-approved PET imaging agent, Cerianna (fluoroestradiol F-18), which is used as an adjunct to biopsy for the detection of estrogen rece ....
GE Healthcare to scale Zionexa’s FDA-approved PET imaging agent, Cerianna (fluoroestradiol F-18), used as an adjunct to biopsy for the detection of estrogen receptor (ER) positive lesions to help inform treatment selection for patients with recurrent or metastatic breast cancer Aims to make Cerianna available to 75% of metastatic breast cancer patients in the U.S. by 2023 Acquisition demonstrates GE Healthcare’s commitment to its precision health vision and builds additional pipeline of oncology and neurology tracers to help physicians personalize treatment 6 May 2021 – GE Healthcare today announced the acquisition of Zionexa, a leading innovator of in-vivo oncology and neurology biomarkers that help enable more personalized healthcare. The company aims to develop and bring to market Zionexa’s pipeline biomarkers, as well as the recently FDA-approved PET imaging agent, Cerianna™ (fluoroestradiol F-18), which is used as an adjunct to biopsy for ....
Nationally Recognized Radiologist and Nuclear Medicine Expert Joins Hoag Family Cancer Institute to Bring Molecular Imaging and Therapy to Orange County News provided by Share this article Share this article NEWPORT BEACH, Calif., Jan. 14, 2021 /PRNewswire/ Hoag Memorial Hospital Presbyterian is building upon its personalized, science-based approach to cancer care with the launch of its Molecular Imaging and Therapy Program, led by nationally recognized expert Gary A. Ulaner, M.D., Ph.D. Dr. Ulaner, who is dual board-certified in radiology and nuclear medicine, recently joined Hoag Family Cancer Institute from Memorial Sloan Kettering Cancer Center where he served as the PET/CT expert on the Breast Cancer and Myeloma Disease Management Teams. He is bringing with him multiple innovative clinical trials, some of which are federally-funded by the National Institutes of Health, that use molecular imaging to detect cancer at a cellular level, well before traditio ....